TAO Synergies Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
4
- Stock Symbol
-
TAOX
- Investments
-
2
- Share Price
-
$1.53
- (As of Friday Closing)
TAO Synergies General Information
Description
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
Contact Information
Website
www.taosynergies.comCorporate Office
- 1185 Avenue of the Americas
- 3rd Floor
- New York, NY 10036
- United States
Corporate Office
- 1185 Avenue of the Americas
- 3rd Floor
- New York, NY 10036
- United States
TAO Synergies Stock Performance
As of 20-Nov-2026, TAO Synergies’s stock price is $1.53. Its current market cap is $12.5M with 8.04M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.53 | $1.73 | $1.50 - $7.85 | $12.5M | 8.04M | 178K | $0.29 |
TAO Synergies Financials Summary
As of 30-Sep-2026, TAO Synergies has a trailing 12-month revenue of $815K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 36,075 | 25,393 | (17,051) | (24,495) |
| Revenue | 815 | 299 | 0 | 0 |
| EBITDA | (6,403) | (29,177) | (14,039) | (7,681) |
| Net Income | (6,269) | (28,737) | (12,769) | (6,039) |
| Total Assets | 28,328 | 25,835 | 17,734 | 31,114 |
| Total Debt | 0 | 0 | 0 | 0 |
TAO Synergies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TAO Synergies Comparisons
Industry
Financing
Details
TAO Synergies Competitors (3)
One of TAO Synergies’s 3 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA |
TAO Synergies Patents
TAO Synergies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240408056-A1 | Methods for repairing nerve damage using pkc activating therapeutic agents | Pending | 12-Jun-2023 | ||
| WO-2024258981-A2 | Methods for repairing nerve damage using pkc activating therapeutic agents | Inactive | 12-Jun-2023 | ||
| WO-2024258981-A3 | Methods for repairing nerve damage using pkc activating therapeutic agents | Inactive | 12-Jun-2023 | ||
| WO-2024019953-A1 | Method of enhancing recovery from long covid | Inactive | 18-Jul-2022 | ||
| EP-4362964-A1 | Method of inducing synaptogenesis by administering angiotensin and analogues thereof | Inactive | 29-Jun-2021 | A61P25/28 |
TAO Synergies Signals
TAO Synergies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
TAO Synergies Investments (2)
TAO Synergies’s most recent deal was a Early Stage VC with PsygaBio. The deal was made on 09-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PsygaBio | 09-Apr-2024 | Early Stage VC | Drug Discovery | ||
| Cannasoul Analytics | 02-Nov-2023 | Later Stage VC | Drug Discovery |
TAO Synergies ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.04 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Software & Services
Industry
of 899
Rank
Percentile
Data Processing
Subindustry
of 98
Rank
Percentile
TAO Synergies Exits (1)
TAO Synergies’s most recent exit was on 09-Apr-2024 from PsygaBio. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| PsygaBio | 09-Apr-2024 | Completed |
|
TAO Synergies FAQs
-
When was TAO Synergies founded?
TAO Synergies was founded in 2012.
-
Where is TAO Synergies headquartered?
TAO Synergies is headquartered in New York, NY.
-
What is the size of TAO Synergies?
TAO Synergies has 4 total employees.
-
What industry is TAO Synergies in?
TAO Synergies’s primary industry is Pharmaceuticals.
-
Is TAO Synergies a private or public company?
TAO Synergies is a Public company.
-
What is TAO Synergies’s stock symbol?
The ticker symbol for TAO Synergies is TAOX.
-
What is the current stock price of TAO Synergies?
As of 20-Nov-2026 the stock price of TAO Synergies is $1.53.
-
What is the current market cap of TAO Synergies?
The current market capitalization of TAO Synergies is $12.5M.
-
What is TAO Synergies’s current revenue?
The trailing twelve month revenue for TAO Synergies is $815K.
-
Who are TAO Synergies’s competitors?
Regenxbio, ACADIA Pharmaceuticals, and Arrowhead Pharmaceuticals are competitors of TAO Synergies.
-
What is TAO Synergies’s annual earnings per share (EPS)?
TAO Synergies’s EPS for 12 months was $0.29.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process